Should the patient be treated with combined aspirin (acetylsalicylic acid) and cilostazol, or with cilostazol alone?

Cilostazol Monotherapy is Preferred Over Combined Aspirin and Cilostazol

For most clinical scenarios, cilostazol should be used as monotherapy rather than in combination with aspirin. The evidence strongly indicates that adding cilostazol to aspirin-clopidogrel dual antiplatelet therapy provides no additional benefit and may increase adverse events, while cilostazol alone demonstrates comparable or superior efficacy to aspirin with a better safety profile.

Clinical Context Determines the Recommendation

Post-PCI/Stent Patients

Do not add cilostazol to aspirin-clopidogrel therapy. The 2012 ACCP guidelines explicitly recommend against this practice 1. The guideline states: "We recommend use of low-dose aspirin 75 to 100 mg daily and clopidogrel 75 mg daily alone rather than cilostazol in addition to these drugs (Grade 1B)" 1.

However, cilostazol can substitute for either aspirin or clopidogrel if the patient has an allergy or intolerance to either drug (Grade 2C) 1. This is the primary role for cilostazol in the post-PCI setting—as a replacement agent, not an addition.

Recent research contradicts this somewhat: a 2025 meta-analysis found that triple therapy (aspirin + clopidogrel + cilostazol) was associated with higher in-hospital mortality and more adverse events (headache, palpitations) compared to dual therapy, with no improvement in cardiovascular outcomes 2. This reinforces the guideline recommendation against adding cilostazol.

Stroke Prevention (Non-Cardioembolic)

Cilostazol monotherapy is an acceptable alternative to aspirin or clopidogrel. The 2012 ACCP stroke guidelines recommend cilostazol 100 mg twice daily as one of several first-line options for secondary stroke prevention 3. The CSPS-2 trial demonstrated that cilostazol was non-inferior to aspirin for stroke recurrence (2.8% vs 3.7% annual rate, HR 0.74) with significantly lower bleeding rates (0.77% vs 1.78%, HR 0.46) 4.

For acute stroke, combining cilostazol with aspirin may reduce early neurological deterioration. A 2012 pilot study showed that aspirin plus cilostazol reduced neurological deterioration within 14 days compared to aspirin alone (6% vs 28%, RR 0.21) 5. A 2025 meta-analysis confirmed that cilostazol-based dual therapy reduced ischemic stroke recurrence (RR 0.54) and any stroke recurrence (RR 0.52) compared to single antiplatelet therapy, with benefits most pronounced in long-term (>3 months) use 6.

Peripheral Artery Disease (PAD)

Cilostazol monotherapy is the preferred approach for claudication symptoms. The 2024 ACC/AHA PAD guidelines and 2024 ESC guidelines support single antiplatelet therapy for PAD 7, 8. Cilostazol 100 mg twice daily improves walking distance and quality of life without increasing bleeding risk 4, 9, 4.

The 2006 ACC/AHA guidelines noted that clopidogrel reduced cardiovascular events by 23.8% more than aspirin specifically in PAD patients 10, but cilostazol remains the symptom-specific therapy of choice for claudication.

Safety Profile Favors Cilostazol Monotherapy

Cilostazol does not prolong bleeding time, even when combined with aspirin. Multiple studies confirm this: a 1999 pharmacokinetic study showed no changes in bleeding time, PT, or aPTT when cilostazol was combined with aspirin 11. A 2005 study demonstrated that while aspirin and clopidogrel alone increased bleeding times, cilostazol did not, and adding cilostazol to aspirin/clopidogrel caused no further bleeding time prolongation 12.

However, cilostazol causes more non-bleeding adverse events. The CSPS-2 trial showed nearly double the discontinuation rate with cilostazol versus aspirin (20% vs 12%) due to headache, diarrhea, palpitations, dizziness, and tachycardia 4. These side effects are mechanism-based (phosphodiesterase III inhibition) and dose-dependent.

Critical Contraindications

Cilostazol is absolutely contraindicated in heart failure of any severity due to the risk of ventricular tachycardia from increased intracellular cyclic AMP 4, 13. This is based on the class effect of phosphodiesterase III inhibitors causing decreased survival in heart failure patients.

Also contraindicated in:

• Active pathologic bleeding (peptic ulcer, intracranial hemorrhage) 13
• Hemostatic disorders 13
• Known hypersensitivity to cilostazol 13

Practical Algorithm

For aspirin-intolerant patients:

• Post-PCI: Use cilostazol 100 mg twice daily + clopidogrel 75 mg daily 1
• Stroke prevention: Use cilostazol 100 mg twice daily as monotherapy 3
• PAD: Use cilostazol 100 mg twice daily as monotherapy 7, 8

For clopidogrel-intolerant patients:

• Post-PCI: Use aspirin 75-100 mg daily + cilostazol 100 mg twice daily 1

For acute ischemic stroke (first 2 weeks):

• Consider aspirin 160-325 mg daily + cilostazol 100 mg twice daily to reduce early neurological deterioration 5, 6
• Transition to monotherapy after acute phase

For chronic secondary prevention:

• Use cilostazol 100 mg twice daily OR aspirin OR clopidogrel—not combinations 3

Common Pitfalls

1. Adding cilostazol to standard dual antiplatelet therapy post-PCI provides no benefit and increases adverse events 1, 2. This is a Grade 1B recommendation against the practice.

2. Failing to screen for heart failure before prescribing cilostazol risks serious arrhythmias. Always assess for any degree of heart failure 4, 13.

3. Underdosing cilostazol. The effective dose is 100 mg twice daily, not once daily 4, 13.

4. Not counseling patients about common side effects. Headache occurs in up to 25% of patients in the first 2 weeks and is the leading cause of discontinuation 4. Setting expectations improves adherence.

5. Using cilostazol in severe renal impairment. The half-life is prolonged, requiring dose adjustment or alternative therapy 4.